Psychotherapy with somatosensory stimulation as a complementary treatment for women with endometriosis-associated pain - a qualitative study.
This qualitative study aimed to explore patients' experiences with a novel treatment approach for endometriosis-associated pain, termed 'sinosomatics'. Specifically, it sought to understand women's experiences of the treatment and its …
Emerging bioengineering breakthroughs in precision diagnosis and therapy for endometriosis and adenomyosis.
Endometriosis and adenomyosis are debilitating gynecological conditions that severely affect the quality of life of women. Traditional diagnostic and treatment methods, including laparoscopic surgery and hormonal therapy, face significant limitations …
Endometriosis in later life: an intersectional analysis from the perspective of epistemic injustice.
Endometriosis, a chronic inflammatory condition affecting 10% of biological women, is widely understudied and particularly overlooked in later life. Discussions surrounding endometriosis predominantly centre on medical gender bias during reproductive …
Telomere length in relation to fecundability and use of assisted reproductive technologies: the Norwegian Mother, Father, and Child Cohort Study - BMC Medicine
Telomere length in relation to fecundability and use of assisted reproductive technologies: the Norwegian Mother, Father, and Child Cohort Study BMC Medicine
Social Determinants of Health and Lifestyle Risk Factors Modulate Genetic Susceptibility for Women's Health Outcomes.
Women's health conditions are influenced by both genetic and environmental factors. Understanding these factors individually and their interactions is crucial for implementing preventative, personalized medicine. However, since genetics and environmental …
Press Release Service: Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - CRISPR Medicine News
Press Release Service: Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial CRISPR Medicine News